This study provides novel insights into the anti-obesity bioactivity of GLT and lays a solid theoretical foundation for the future development of anti-obesity pharmaceuticals and functional foods. The gene discussed is NOP53; the disease is obesity due to melanocortin 4 receptor deficiency.